LaserGen

Advanced Analytical markets CE instruments, reagents, and software for nucleic acid analysis while Lasergen is a next-generation sequencing technology developer.

The firm's $80 investment in Lasergen sets the stage for it to develop an integrated sample-to-result clinical genomics workflow by 2020.

Agilent said it will work with Lasergen to build a clinical sequencing workflow based on the smaller firm's Lightning Terminators sequencing chemistry.

LaserGen has named Mimi Healy CEO and to its board of directors. She is taking over from founder Michael Metzker, who developed and patented the company's proprietary Lightning Terminators.

By Julia Karow
This article has been updated to include information about Roche/IBM and Genia.

LaserGen has raised $5 million in a Series A financing round, which it will use to demonstrate accurate sequencing of the Escherichia coli genome and to continue developing its next-generation sequencing system.

Last week, the Baylor College of Medicine spinout disclosed that it has teamed up with National Instruments to build and validate a prototype sequencer that uses its "Lightning Terminator" chemistry.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.